Lateral hip pain is one of the most common complaints we see in runners, walkers, and active people of all levels, and it is also one of the most frequently mislabelled. In most cases, the problem is not isolated bursitis but a gluteal tendinopathy, a condition that sits within the broader spectrum of greater trochanteric pain syndrome (GTPS). Understanding this distinction matters, because it changes how the problem is assessed, how it is treated, and why an ultrasound-guided injection around the hip is a narrow, specific tool rather than a stand-alone solution.
This article explains the modern understanding of GTPS and the precise role of an ultrasound-guided injection around the greater trochanter. We will cover why “hip bursitis” is usually the wrong label, how GTPS is diagnosed and what imaging actually adds, who is a reasonable candidate for an injection, and what the injection can and cannot do. We will also compare ultrasound guidance with a landmark approach, set out the rehabilitation that has to follow for the result to hold, and look honestly at the evidence for options beyond injection. At PSM, our specialist sports medicine team brings professional-sport level assessment, diagnostics, treatment and rehabilitation together in one clinic, so you can understand the problem and make an informed decision about your care.
Why “Hip Bursitis” Is Usually the Wrong Label
Most people arrive at a clinic already convinced they have hip bursitis. It makes sense: the pain sits directly over the bony lump on the outside of the hip, and the name sounds plausible. But “trochanteric bursitis” is a legacy term rather than an accurate diagnosis.
Surgical, histological and imaging studies now attribute greater trochanteric pain syndrome (GTPS) primarily to tendinopathy of gluteus medius, gluteus minimus and tensor fascia latae, with bursal inflammation usually a secondary finding rather than the cause.
That distinction changes everything in practice. A bursitis label points toward inflammation and a steroid, yet histological studies have not shown inflammation in bursa specimens. A tendinopathy label frames the problem as load tolerance, which responds to progressive loading.
The problem is common. GTPS is a frequent cause of lateral hip pain presenting in primary care and sports medicine clinics.
GTPS is now the accepted umbrella term, and the words a clinician uses shape the treatment a patient is offered. Accurate terminology matters with other tendons too; the evidence behind shockwave therapy shows why outdated labels can lead to the wrong treatment choice entirely.
What Greater Trochanteric Pain Syndrome Actually Is
That shift in terminology matters because GTPS is not one lesion. A recent review describes it as a spectrum in which abductor (gluteal) tendinopathy, trochanteric bursitis and external coxa saltans (snapping hip) can coexist, with abductor tendon pathology the most frequent driver. In plain terms, gluteus medius and minimus insert onto the greater trochanter and help control the pelvis during single-leg stance, so they are loaded with every step and every stair.
Compression is the common aggravating mechanism. Standing with the hip dropped or adducted, sitting with crossed legs and lying on the affected side all press the tendon against the trochanter. The pattern is consistent: pain lying on the affected side, and pain that worsens with walking and stairs.
It presents most often in women, with a female predominance of roughly four to one, commonly in the fourth to sixth decades. Runners and other active people feature, and both sedentary and highly active people appear. The clinical picture, rather than the label alone, determines what comes next.
How GTPS Is Diagnosed: Clinical Signs, Then the Right Scan
GTPS is a clinical diagnosis. No single test is reliable on its own, so a specialist assessment combines findings rather than relying on any one manoeuvre. That assessment looks for tenderness over the greater trochanter, pain on resisted hip abduction and external rotation, and pain reproduced by a 30-second single-leg stand.
Imaging does not confirm GTPS. It is used mainly to exclude other causes of lateral hip pain and to assess tendon structure. Hip osteoarthritis, femoroacetabular impingement, lumbar spondylosis with referred pain, inguinal hernia and avascular necrosis can all mimic it. Red flags alter the pathway and warrant further investigation, including significant trauma, an inability to weight-bear, or features that raise concern about a tendon tear or other serious pathology.
Ultrasound is positioned honestly. Its main value is real-time guidance of an ultrasound-guided injection and showing tendon and bursal change using diagnostic ultrasound for tendon problems, not making the initial diagnosis.
Who Is a Reasonable Candidate for an Ultrasound Guided Injection
Once the diagnosis is secure, candidacy narrows. An ultrasound-guided greater trochanter injection is a targeted adjunct for a specific clinical picture, not a routine step for lateral hip pain.
Reasonable candidates typically have:
- a confident clinical diagnosis of GTPS;
- pain that is interfering with sleep, walking or work;
- a loading programme already trialled and not tolerated because of pain.
The common bridging scenario is the patient who cannot start rehabilitation because every step hurts, or who needs symptoms settled for a defined period, such as returning to work or a key event. Here the injection buys a window for loading.
Choose another route when there is diagnostic uncertainty, a suspected tendon tear needing a surgical opinion, a bleeding risk, an active infection, or poorly controlled diabetes if corticosteroid is considered. Repeated injections that have changed nothing should prompt reassessment, not another injection.
Plan for a single guided injection, not a course. Judge it by whether rehabilitation progressed. This stepwise logic mirrors the structured approach we use for knee osteoarthritis care in Cardiff: diagnosis first, intervention second.
What the Injection Does, and What It Cannot Do
Once candidacy is established, expectations should be set precisely. Ultrasound-guided corticosteroid injection around the hip can reduce pain early, but the evidence is time-limited. In a cohort of 127 patients, 41% achieved at least 50% pain reduction at rest at 6 weeks, falling to 37% at 6 months and 36% at 12 months. A 2025 review found corticosteroid injection combined with physiotherapy was more effective for acute symptoms than physiotherapy alone, while targeted physiotherapy and home exercise delivered long-term benefit for most patients, sometimes slowly. The injection is therefore a window that makes loading tolerable, not a treatment of the tendon pathology itself; its value depends almost entirely on what happens in the following weeks. Realistic downsides include a post-injection pain flare lasting a few days, skin and fat atrophy or lightening at the site, a small infection risk, and a transient rise in blood glucose. Repeated injections into the same tendon warrant caution. Other injectable strategies, such as high-volume tendon injection, have separate indications.
Ultrasound Guidance Versus a Landmark Approach
The same principle applies to how the injection is delivered. A landmark, or blind, injection uses bony landmarks and an assumed depth. An ultrasound-guided injection in the hip lets the clinician see the gluteus medius and minimus tendons, the bursa and the needle tip in real time. That allows placement into the bursa or tendon sheath rather than tendon substance, aims to keep injectate away from skin and subcutaneous tissue, and targets exactly what the scan shows. The scan can also identify a gluteal tendon tear or other pathology that would change the plan during the same appointment. The evidence needs stating plainly: guidance improves the precision of needle placement, but current data do not prove better long-term GTPS outcomes than a landmark approach. The case rests on precision, not certainty of result.
The Rehabilitation That Has to Follow for the Result to Hold
Precision placement only creates the opportunity; outcomes depend on the loading programme that follows. Begin with load management rather than rest: reduce compressive and high-impact activity briefly, keep walking and daily tasks within a tolerable range, and avoid a complete stop that deconditions the tendon. In the days after injection, ease off aggravating loads, then return to the programme by plan, not by waiting for pain to dictate.
Progress by principle, not rigid protocol: isometric holds for control, slow heavy isotonic work for gluteus medius and minimus, then single-leg and functional tasks such as step-downs, with impact work only when running goals demand it and criteria allow. Manage the tendon’s compressive load as well as its tensile load. Judge progress over months, reviewing pain-free walking distance, single-leg stand tolerance and measured abductor strength at defined intervals.
Options Beyond Injection: An Honest Evidence Hierarchy
Rehabilitation is not one option among several; it is the foundation the others sit on. The 2025 narrative review places targeted physiotherapy and home exercise at the top of the hierarchy, concluding they deliver long-term benefit for most patients while acknowledging no clear consensus on the single optimal package.
The adjuncts sit below, with sharply differing evidence.
Shockwave is limited but promising. One review-cited result reported meaningful improvement on visual analogue pain scores versus controls, without notable adverse effects.
Platelet-rich plasma remains unproven. A randomised study of 24 patients favoured PRP over corticosteroid on pain scores at 24 weeks with no complications reported, but the sample was small and the authors called for further work; the 2025 review calls the evidence inconclusive.
Corticosteroid is a short-term tool. It is useful for the acute phase when paired with rehabilitation, not as a standalone treatment.
Surgery is not a first-line answer. It is reserved for confirmed tendon tears or persistent disabling symptoms after prolonged, well-conducted conservative management, with referral to orthopaedic colleagues where appropriate. If you are unsure which clinician is right, this guide to choosing a musculoskeletal specialist doctor clarifies the differences.
What that timeline looks like is the next question.
Realistic Timelines: What Improvement Actually Looks Like
Whichever route is chosen, expect months, not weeks. One review-cited study reported symptom resolution at 15 months in 60.5% of patients; treat that as encouragement, not a two-week promise. After a guided injection, a short flare in the first days is possible, followed by a usable window over the next few weeks. The main loading block then runs for roughly 12 weeks, with continued improvement over 6 to 12 months. If progress stalls, revisit the diagnosis, review load and compressive positions, and check adherence before adding another intervention. Where osteoarthritis rather than tendinopathy is found, separate pathways exist, including Arthrosamid for knee osteoarthritis.
What to Take Away
Patience and proper assessment matter more than any single intervention. Four points summarise the practical message.
- Get the label right. Pain on the outside of the hip is typically gluteal tendinopathy rather than bursitis. That distinction changes what will actually help: loading, not simply rest and a steroid.
- Get examined properly. A combined clinical assessment, with imaging used to exclude other causes rather than to confirm greater trochanteric pain syndrome, is what makes the diagnosis reliable.
- Treat an ultrasound-guided greater trochanter injection as a window to load through. It is not a fix, and never a substitute for rehabilitation.
- Expect slow progress. Judge it against objective markers over months, not days.
Conclusion
At Pro Sports Medicine in Cardiff, the integration of professional sport level diagnostics, ultrasound-guided procedures and structured rehabilitation within a single pathway means your treatment is planned as a coherent whole. If your lateral hip pain has persisted despite rest, or you are uncertain whether an injection is appropriate, a specialist assessment is the sensible next step.
